Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this module, Srdan Verstovsek, MD, PhD, and Amy E. DeZern, MD, MHS, offer an overview of some of the myeloproliferative neoplasm (MPNs) and myelodysplastic syndromes (MDS) studies presented at the 2020 ASH Annual Meeting. The studies covered first-line and second-line treatments for MPN and MDS as well as therapies to treat the anemia associated with these diseases.
The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.
Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.
Before continuing with this educational activity, please take a moment to answer the following questions.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
